RS57377B1 - Policiklični lpa1 antagonist i njegove primene - Google Patents

Policiklični lpa1 antagonist i njegove primene

Info

Publication number
RS57377B1
RS57377B1 RS20180740A RSP20180740A RS57377B1 RS 57377 B1 RS57377 B1 RS 57377B1 RS 20180740 A RS20180740 A RS 20180740A RS P20180740 A RSP20180740 A RS P20180740A RS 57377 B1 RS57377 B1 RS 57377B1
Authority
RS
Serbia
Prior art keywords
polycyclic
lpa1 antagonist
lpa1
antagonist
polycyclic lpa1
Prior art date
Application number
RS20180740A
Other languages
English (en)
Inventor
Jason Edward Brittain
Thomas Jon Seiders
Christopher David King
Victor W Rosso
Original Assignee
Amira Pharmaceuticals Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc, Bristol Myers Squibb Co filed Critical Amira Pharmaceuticals Inc
Publication of RS57377B1 publication Critical patent/RS57377B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
RS20180740A 2010-12-07 2011-12-07 Policiklični lpa1 antagonist i njegove primene RS57377B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42059910P 2010-12-07 2010-12-07
PCT/US2011/063817 WO2012078805A1 (en) 2010-12-07 2011-12-07 Polycyclic lpa1 antagonist and uses thereof
EP11805292.7A EP2648726B1 (en) 2010-12-07 2011-12-07 Polycyclic lpa1 antagonist and uses thereof

Publications (1)

Publication Number Publication Date
RS57377B1 true RS57377B1 (sr) 2018-08-31

Family

ID=45446189

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180740A RS57377B1 (sr) 2010-12-07 2011-12-07 Policiklični lpa1 antagonist i njegove primene

Country Status (25)

Country Link
US (2) US9556133B2 (sr)
EP (2) EP2648726B1 (sr)
JP (1) JP6030567B2 (sr)
KR (1) KR101875246B1 (sr)
CN (2) CN103596566B (sr)
AU (2) AU2011338417B2 (sr)
BR (1) BR112013013950A2 (sr)
CA (1) CA2820884A1 (sr)
CY (1) CY1120342T1 (sr)
DK (1) DK2648726T3 (sr)
EA (1) EA024967B1 (sr)
ES (1) ES2674174T3 (sr)
HR (1) HRP20180970T1 (sr)
HU (1) HUE040397T2 (sr)
IL (1) IL226698B (sr)
LT (1) LT2648726T (sr)
MX (1) MX347544B (sr)
NO (1) NO2648726T3 (sr)
PL (1) PL2648726T3 (sr)
PT (1) PT2648726T (sr)
RS (1) RS57377B1 (sr)
SG (1) SG191041A1 (sr)
SI (1) SI2648726T1 (sr)
TR (1) TR201809293T4 (sr)
WO (1) WO2012078805A1 (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2014104372A1 (ja) 2012-12-28 2014-07-03 宇部興産株式会社 ハロゲン置換へテロ環化合物
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
AU2014274830B2 (en) 2013-06-07 2017-11-09 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
WO2015066456A1 (en) 2013-10-31 2015-05-07 Bristol-Myers Squibb Company Radioligands for imaging the lpa-1 receptor
SI3077047T1 (sl) * 2013-12-04 2019-09-30 Galmed Research & Development Ltd. Soli aramchola
GB201410741D0 (en) * 2014-06-17 2014-07-30 Babraham Inst And University Of Birmingham The Novel diagnostic and therapeutic method
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
US20180360803A1 (en) * 2015-11-20 2018-12-20 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of nash
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
CN108318447B (zh) * 2018-05-04 2020-12-18 山东大学 一种基于近红外光谱技术快速测定吡喹酮对映体组成的方法
HUE061559T2 (hu) 2018-06-07 2023-07-28 Idorsia Pharmaceuticals Ltd Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk
KR102224677B1 (ko) * 2018-08-23 2021-03-08 가천대학교 산학협력단 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
KR20210060546A (ko) * 2018-09-18 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
JP2023504415A (ja) 2019-12-04 2023-02-03 イドーシア ファーマシューティカルズ リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
KR102393079B1 (ko) 2020-02-28 2022-04-29 한국화학연구원 가축 호흡기 질환의 예방 또는 치료용 조성물
CN111608208B (zh) * 2020-05-19 2022-01-11 浙江鲁班建材科技股份有限公司 一种时间可控制的吸水膨胀堵漏型预铺卷材
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN115867556A (zh) 2020-06-03 2023-03-28 吉利德科学公司 Lpa受体拮抗剂及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR102463504B1 (ko) 2022-08-23 2022-11-04 주식회사 에네스지 원전 습분분리재열기의 종단온도차 보정 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
PT1258484E (pt) * 2000-02-18 2009-04-03 Kyowa Hakko Kirin Co Ltd Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
WO2003055494A1 (en) 2001-12-21 2003-07-10 Avmax, Inc. Use of ugt inhibitors to increase bioavailability
US20040014648A1 (en) 2002-05-17 2004-01-22 Faust Pharmaceuticals Methods for the prevention and/or the treatment of neurological disorders
EP1638551B1 (en) 2003-05-19 2011-12-21 Irm Llc Immunosuppressant compounds and compositions
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
EP1915369A4 (en) 2005-08-11 2010-09-08 Merck Frosst Canada Ltd NEW SUBSTITUTED 1,2,3-TRIAZOLYLMETHYLBENZOTHIOPHENE OR ENDOLE AND THEIR USE AS INHIBITORS OF LEUKOTRIENBIOSYNTHESIS
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
JP2009523820A (ja) 2006-01-23 2009-06-25 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼの三環系抑制剤
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors

Also Published As

Publication number Publication date
MX347544B (es) 2017-05-02
US9556133B2 (en) 2017-01-31
KR101875246B1 (ko) 2018-07-05
WO2012078805A1 (en) 2012-06-14
HUE040397T2 (hu) 2019-03-28
LT2648726T (lt) 2018-06-25
SG191041A1 (en) 2013-08-30
SI2648726T1 (en) 2018-06-29
EP2648726A1 (en) 2013-10-16
PT2648726T (pt) 2018-06-25
KR20130124524A (ko) 2013-11-14
DK2648726T3 (da) 2018-07-16
US20130253023A1 (en) 2013-09-26
AU2016238848A1 (en) 2016-10-27
CN107721940A (zh) 2018-02-23
IL226698B (en) 2018-05-31
JP2013544890A (ja) 2013-12-19
TR201809293T4 (tr) 2018-07-23
EA024967B1 (ru) 2016-11-30
NO2648726T3 (sr) 2018-09-01
HRP20180970T1 (hr) 2018-08-10
ES2674174T3 (es) 2018-06-27
US20170121295A1 (en) 2017-05-04
EP3360552A1 (en) 2018-08-15
PL2648726T3 (pl) 2018-10-31
CN103596566B (zh) 2017-08-25
EP2648726B1 (en) 2018-04-04
AU2016238848B2 (en) 2018-03-29
MX2013006394A (es) 2013-09-13
EA201390840A1 (ru) 2013-10-30
CN103596566A (zh) 2014-02-19
AU2011338417A1 (en) 2013-07-25
AU2011338417B2 (en) 2016-12-01
CA2820884A1 (en) 2012-06-14
CY1120342T1 (el) 2019-07-10
JP6030567B2 (ja) 2016-11-24
BR112013013950A2 (pt) 2016-09-27

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
IL226698B (en) Polycyclic lpa1 antagonist and uses thereof
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
ZA201208173B (en) Peptices and their use
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
AP2013006947A0 (en) Compounds and their use
EP2575453A4 (en) OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2615094A4 (en) SESTERTERPEN COMPOUNDS AND THEIR USE
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201014319D0 (en) Compounds and uses thereof
GB201017822D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201002337D0 (en) Compounds and their use
GB201000305D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use